Asset Details
Do you wish to reserve the book?
The tumor cell‐derived matrix of lobular breast cancer: a new vulnerability
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The tumor cell‐derived matrix of lobular breast cancer: a new vulnerability
Do you wish to request the book?
The tumor cell‐derived matrix of lobular breast cancer: a new vulnerability
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The tumor cell‐derived matrix of lobular breast cancer: a new vulnerability
2021
Overview
Invasive lobular carcinoma (ILC) of the breast is a very common disease. Despite its prevalence, these tumors are relatively understudied. One reason for this is a relative lack of models for ILC. This challenge was addressed by Brisken and colleagues through development of an intraductal injection‐based xenograft system for the study of ERα
+
breast cancers, including both ILC and more common invasive ductal carcinoma (IDC; Sflomos
et al
, 2016). In this issue of
EMBO Molecular Medicine,
the same group have applied intraductal injection‐based xenografts to identify novel tumor cell‐specific transcriptional signatures in ILC (Sflomos
et al
, 2021). In doing so they found overexpression of lysyl oxidase‐like 1 (LOXL1) to be both responsible for the frequently seen stiff collagen‐rich extracellular matrix of lobular breast cancer and essential for their robust growth and metastatic dissemination
in vivo
, thereby identifying a novel therapeutic target.
Graphical Abstract
Despite its prevalence, invasive lobular carcinoma (ILC) is relatively understudied. In their recent study, Brisken and colleagues apply intraductal injection based xenografts to characterize tumor‐cell specific transcriptional signatures in ILC and identify a novel therapeutic target.
